Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
The growing list of human viruses: Are we prepared for the next outbreak?

The growing list of human viruses: Are we prepared for the next outbreak?

E64FC26 inhibits inflammation and joint destruction in rheumatoid arthritis models

E64FC26 inhibits inflammation and joint destruction in rheumatoid arthritis models

New gene modification enhances CAR-T cell effectiveness against cancer

New gene modification enhances CAR-T cell effectiveness against cancer

New study confirms CAR T cell therapy does not cause secondary cancers

New study confirms CAR T cell therapy does not cause secondary cancers

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

UIC scientists redesign asparaginase to minimize leukemia treatment side effects

UIC scientists redesign asparaginase to minimize leukemia treatment side effects

Oral fecal transplantation could help prevent graft-versus-host disease in stem cell transplant patients

Oral fecal transplantation could help prevent graft-versus-host disease in stem cell transplant patients

Developmental epigenetic changes could shape cancer risk later in life

Developmental epigenetic changes could shape cancer risk later in life

Immune environment found to influence success of leukemia immunotherapy

Immune environment found to influence success of leukemia immunotherapy

New approach uses peptides to enhance anti-tumor drug formulations

New approach uses peptides to enhance anti-tumor drug formulations

Researchers identify key factors for successful donor lymphocyte infusion in AML patients

Researchers identify key factors for successful donor lymphocyte infusion in AML patients

New approach to treating ependymoma with leukemia drug

New approach to treating ependymoma with leukemia drug

$2.5 Million Grant Awarded to Indiana University School of Medicine, Beckman Coulter Life Sciences to Expand Leukemia and Lymphoma Testing in Africa

$2.5 Million Grant Awarded to Indiana University School of Medicine, Beckman Coulter Life Sciences to Expand Leukemia and Lymphoma Testing in Africa

Drug in breast cancer trials shows potential for treating blood cancers

Drug in breast cancer trials shows potential for treating blood cancers

PFAS in US water linked to increased cancer risk

PFAS in US water linked to increased cancer risk

Mouse protein disrupts cancer-causing epigenetic changes in human colorectal cancer

Mouse protein disrupts cancer-causing epigenetic changes in human colorectal cancer

New drug cocktail enhances CAR-T cells for cancer treatment

New drug cocktail enhances CAR-T cells for cancer treatment

Obesity at cancer diagnosis linked to higher risk of death in children

Obesity at cancer diagnosis linked to higher risk of death in children

Breakthrough microscopy technique reveals how antibodies target cancer cells

Breakthrough microscopy technique reveals how antibodies target cancer cells

Computer model helps tailor CML treatment to individual patients

Computer model helps tailor CML treatment to individual patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.